Table 2. Genotype and Allele Frequencies in the Analyzed Population (n = 991).
| MTHFR polymorphism group | Genotype, n (%) | P* | Alleles, n (%) | P* | |||
|---|---|---|---|---|---|---|---|
| CC | CT | TT | C | T | |||
| C677T | |||||||
| Control (n = 202) | 76 (37.6) | 98 (48.5) | 28 (13.9) | 250 (62.9) | 154 (38.1) | ||
| Colorectal cancer (n = 550) | 163 (24.7) | 268 (48.7) | 119 (21.6) | 0.023 | 594 (54.0) | 506 (46.0) | 0.06 |
| Esophageal/gastric cancer (n = 138) | 37 (26.8) | 69 (50.0) | 32 (23.2) | 0.031 | 143 (51.8) | 133 (48.2) | 0.009 |
| Pancreatic/biliar cancer (n = 97) | 32 (33.0) | 51 (52.6) | 14 (14.4) | 0.733 | 115 (59.3) | 79 (40.7) | 0.541 |
| AA | AT | TT | A | T | |||
| A1298T | |||||||
| Control (n = 202) | 103 (51.0) | 80 (39.6) | 19 (9.4) | 286 (70.8) | 118 (29.2) | ||
| Colorectal cancer (n = 553) | 263 (47.5) | 232 (41.9) | 58 (10.6) | 0.695 | 758 (68.5) | 348 (31.5) | 0.401 |
| Esophageal/gastric cancer (n = 138) | 60 (43.8) | 66 (48.2) | 11 (8.0) | 0.298 | 186 (67.9) | 88 (32.1) | 0.419 |
| Pancreatic/biliar cancer (n = 99) | 49 (49.5) | 45 (45.5) | 5 (5.0) | 0.340 | 143 (72.2) | 55 (27.8) | 0.716 |
*Difference in genotypes or alleles distribution between each cancer group and the control group assessed by X2 statistical testing.